JP2023518269A - Ｃｏｖｉｄ－１９のための吸入療法 - Google Patents

Ｃｏｖｉｄ－１９のための吸入療法 Download PDF

Info

Publication number
JP2023518269A
JP2023518269A JP2022556252A JP2022556252A JP2023518269A JP 2023518269 A JP2023518269 A JP 2023518269A JP 2022556252 A JP2022556252 A JP 2022556252A JP 2022556252 A JP2022556252 A JP 2022556252A JP 2023518269 A JP2023518269 A JP 2023518269A
Authority
JP
Japan
Prior art keywords
subject
mesylate
pharmaceutical composition
composition
camostat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518269A5 (enExample
Inventor
タケシ イリエ
エルフェリ，ウアテク
Original Assignee
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2023518269A publication Critical patent/JP2023518269A/ja
Publication of JP2023518269A5 publication Critical patent/JP2023518269A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022556252A 2020-03-18 2021-03-18 Ｃｏｖｉｄ－１９のための吸入療法 Pending JP2023518269A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991561P 2020-03-18 2020-03-18
US62/991,561 2020-03-18
PCT/US2021/022997 WO2021188815A1 (en) 2020-03-18 2021-03-18 Inhalational therapy for covid-19

Publications (2)

Publication Number Publication Date
JP2023518269A true JP2023518269A (ja) 2023-04-28
JP2023518269A5 JP2023518269A5 (enExample) 2024-03-27

Family

ID=77771385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556252A Pending JP2023518269A (ja) 2020-03-18 2021-03-18 Ｃｏｖｉｄ－１９のための吸入療法

Country Status (5)

Country Link
US (1) US20230165826A1 (enExample)
EP (1) EP4121037A4 (enExample)
JP (1) JP2023518269A (enExample)
CA (1) CA3171958A1 (enExample)
WO (1) WO2021188815A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021202708A1 (en) * 2020-03-31 2021-10-07 Ensysce Biosciences, Inc. Methods for treating viral infections with nafamostat
EP4267125A4 (en) * 2020-12-22 2024-06-26 Ege Universitesi Development of an innovative inhalation formulation of nafamostat mesylate for the management of covid-19
CN118121605B (zh) * 2024-02-28 2025-09-09 中国科学院武汉病毒研究所 去甲乌药碱在防治新型冠状病毒中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003089632A (ja) * 2001-09-17 2003-03-28 Otsuka Pharmaceut Factory Inc 注射用水性製剤
JP2005527538A (ja) * 2002-03-19 2005-09-15 サイデックス・インコーポレイテッド 保存剤としてのスルホアルキルエーテルシクロデキストリンの使用
JP2007517067A (ja) * 2003-12-31 2007-06-28 サイデックス・インコーポレイテッド スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2008537750A (ja) * 2005-04-14 2008-09-25 ノバルティス アクチエンゲゼルシャフト 有機化合物
CN111803483A (zh) * 2020-01-21 2020-10-23 中国人民解放军军事科学院军事医学研究院 苯甲酸酯类化合物在治疗SARS-CoV-2感染方面的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0859503A (ja) * 1994-08-26 1996-03-05 Teijin Ltd ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤
JP2005139085A (ja) * 2003-11-04 2005-06-02 Ono Pharmaceut Co Ltd 顆粒
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
DE102011108346A1 (de) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Verwendung von Hemmstoffen der TMPRSS2 als Arzneimittel
BR112015003851A2 (pt) * 2012-08-21 2017-08-08 Glaxo Group Ltd composições compreendendo um domínio variável único e mesilato de camostato (cm)
RU2622747C2 (ru) * 2015-10-22 2017-06-19 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) Способ и средство для лечения реактивного артрита хламидийной этиологии

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003089632A (ja) * 2001-09-17 2003-03-28 Otsuka Pharmaceut Factory Inc 注射用水性製剤
JP2005527538A (ja) * 2002-03-19 2005-09-15 サイデックス・インコーポレイテッド 保存剤としてのスルホアルキルエーテルシクロデキストリンの使用
JP2007517067A (ja) * 2003-12-31 2007-06-28 サイデックス・インコーポレイテッド スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2008537750A (ja) * 2005-04-14 2008-09-25 ノバルティス アクチエンゲゼルシャフト 有機化合物
CN111803483A (zh) * 2020-01-21 2020-10-23 中国人民解放军军事科学院军事医学研究院 苯甲酸酯类化合物在治疗SARS-CoV-2感染方面的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTIMICROB. AGENTS CHEMOTHER., vol. 60, no. 11, JPN6025008119, 2016, pages 6532 - 6539, ISSN: 0005542884 *
CELL, vol. 181, JPN6025008118, 5 March 2020 (2020-03-05), pages 271 - 280, ISSN: 0005542883 *

Also Published As

Publication number Publication date
EP4121037A1 (en) 2023-01-25
CA3171958A1 (en) 2021-09-23
WO2021188815A1 (en) 2021-09-23
US20230165826A1 (en) 2023-06-01
EP4121037A4 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
AU710821B2 (en) Fluticasone propionate formulations
ES2556229T3 (es) Aerosoles para suministro sinunasal de fármacos
ES2399279T3 (es) Formulaciones de tobramicina para el tratamiento de infecciones endobronquiales
JP2023518269A (ja) Ｃｏｖｉｄ－１９のための吸入療法
Hatipoglu et al. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs
ES2928050T3 (es) Peptidomimético de horquilla beta con actividad inhibidora de elastasa y formas de dosificación en aerosol del mismo
CN111956630A (zh) 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用
US20230355517A1 (en) Use of active substances with antiviral, anti malarial, and/or mucolytic properties in the treatment of viral lung diseases including covid-19 by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
BR112020015646A2 (pt) Formulações intranasais de epinefrina e métodos para o tratamento de doença
Garcia-Contreras et al. Aerosol treatment of cystic fibrosis
CN116744934A (zh) 用于治疗病毒性呼吸疾病的吸入性他汀类药物
AU2021326382B2 (en) Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
BR112021009572A2 (pt) métodos e composições para prevenção ou tratamento de exacerbações agudas com imunoglobulina policlonal
US20220339099A1 (en) Compositions of interleukin-1 receptor antagonist
RU2843523C1 (ru) Применение композиции на основе гепарина при лечении вирусных заболеваний легких, острых и/или хронических заболеваний легких с помощью ингалятора «мягкого тумана» или небулайзера с технологией вибрирующей сетки посредством ингаляционного пути введения
WO2025186422A1 (en) Treatment and prevention of respiratory diseases
CA3204080A1 (en) Compositions, devices, and methods for treating respiratory disorders
WO2025186423A1 (en) Immunoglobulin composition and method of generating an aerosol
WO2022166724A1 (zh) 一种福多司坦吸入用溶液制剂及其制备方法和用途
TUTOR Pulmonary drug delivery systems based on polymeric micro and nanoparticles for the treatment of cystic fibrosis
Raposo Systematic devolopment [development] of formulations suitable for pulmonary applications by nebulisation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902